Clean Yield Group Trims Stock Holdings in GSK plc (NYSE:GSK)

Clean Yield Group reduced its position in GSK plc (NYSE:GSK - Free Report) by 10.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 179,114 shares of the pharmaceutical company's stock after selling 20,949 shares during the quarter. GSK makes up about 2.3% of Clean Yield Group's portfolio, making the stock its 8th largest position. Clean Yield Group's holdings in GSK were worth $6,939,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GSK. Indiana Trust & Investment Management Co boosted its stake in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Sierra Ocean LLC bought a new position in GSK during the fourth quarter worth $32,000. Parkside Financial Bank & Trust boosted its stake in GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after acquiring an additional 818 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in GSK during the fourth quarter worth $40,000. Finally, Golden State Wealth Management LLC bought a new position in GSK during the fourth quarter worth $38,000. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $41.22 on Friday. The firm has a 50-day moving average of $37.59 and a 200-day moving average of $36.41. The company has a market cap of $84.48 billion, a P/E ratio of 25.92, a P/E/G ratio of 1.12 and a beta of 0.52. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a one year low of $31.72 and a one year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.43 earnings per share. Equities research analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.09%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 86.60%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.